论文部分内容阅读
目的探讨替米沙坦辅助治疗糖尿病肾病的临床价值。方法选取我院2012年1月~12月收治的65例糖尿病肾病患者。首先对患者进行基础治疗,严格控制血脂和血糖,可相应的采取胰岛素或口服药物进行控制,空腹血糖达标FBG需<7.0mmol/L,PBG<10.0mmol/L。患者均控制血脂达标,可采取他汀类降脂药物,并可给予阿司匹林肠溶片进行治疗。其次患者在基础治疗上添加替米沙坦治疗。观察分析患者的临床症状。结果 55例患者治疗后DBP、SBP、Cr、BUN、24UP和HbA1c的改善情况明显低于治疗前,临床症状得到显著改善,P<0.05,差异具有统计学意义。结论替米沙坦辅助治疗糖尿病肾病,取得显著疗效,能有效减少患者的蛋白尿,改善肾功能,起到保护作用,具有较高的临床价值。
Objective To investigate the clinical value of telmisartan in the treatment of diabetic nephropathy. Methods Sixty-five patients with diabetic nephropathy admitted in our hospital from January 2012 to December 2012 were selected. First of all, basic treatment of patients with strict control of blood lipids and blood glucose can be taken accordingly insulin or oral medication control, fasting blood glucose compliance FBG <7.0mmol / L, PBG <10.0mmol / L. Patients are controlled blood lipids, can take statins lipid-lowering drugs, and can be given aspirin enteric-coated tablets for treatment. Second, patients were treated with telmisartan on basic treatment. Observe and analyze the patient’s clinical symptoms. Results The improvement of DBP, SBP, Cr, BUN, 24UP and HbA1c in 55 patients was significantly lower than that before treatment, and the clinical symptoms were significantly improved (P <0.05). The difference was statistically significant. Conclusion Telmisartan adjuvant treatment of diabetic nephropathy, and achieved a significant effect, can effectively reduce the patient’s proteinuria, improve renal function, play a protective role, with high clinical value.